Cartesian Therapeutics (RNAC) Projected to Post Earnings on Thursday

Cartesian Therapeutics (NASDAQ:RNAC) is expected to post its results before the market opens on Thursday, March 12th. Analysts expect Cartesian Therapeutics to post earnings of ($0.82) per share and revenue of $0.10 million for the quarter.

Cartesian Therapeutics Price Performance

Shares of RNAC opened at $7.87 on Thursday. The company has a 50-day moving average of $7.15 and a two-hundred day moving average of $8.26. The stock has a market cap of $204.62 million, a price-to-earnings ratio of -5.04 and a beta of 0.42. Cartesian Therapeutics has a one year low of $5.98 and a one year high of $18.80.

Insider Buying and Selling at Cartesian Therapeutics

In other news, CFO Blaine Davis sold 10,591 shares of the company’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $6.82, for a total value of $72,230.62. Following the transaction, the chief financial officer directly owned 121,220 shares of the company’s stock, valued at approximately $826,720.40. This represents a 8.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 60.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Rhumbline Advisers raised its stake in shares of Cartesian Therapeutics by 27.5% during the 1st quarter. Rhumbline Advisers now owns 13,006 shares of the company’s stock worth $171,000 after purchasing an additional 2,805 shares in the last quarter. Wells Fargo & Company MN increased its holdings in Cartesian Therapeutics by 49.2% in the fourth quarter. Wells Fargo & Company MN now owns 11,762 shares of the company’s stock worth $85,000 after buying an additional 3,878 shares during the last quarter. Bank of America Corp DE raised its position in Cartesian Therapeutics by 133.0% during the second quarter. Bank of America Corp DE now owns 13,933 shares of the company’s stock valued at $145,000 after acquiring an additional 7,952 shares in the last quarter. Geode Capital Management LLC lifted its stake in Cartesian Therapeutics by 5.7% in the fourth quarter. Geode Capital Management LLC now owns 255,539 shares of the company’s stock valued at $1,843,000 after acquiring an additional 13,710 shares during the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new stake in Cartesian Therapeutics in the fourth quarter valued at approximately $112,000. Hedge funds and other institutional investors own 86.95% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Needham & Company LLC raised their price objective on shares of Cartesian Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Weiss Ratings restated a “sell (e+)” rating on shares of Cartesian Therapeutics in a report on Monday, December 29th. HC Wainwright lowered their price target on Cartesian Therapeutics from $40.00 to $30.00 and set a “buy” rating on the stock in a report on Wednesday, November 19th. Wall Street Zen lowered Cartesian Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, BTIG Research increased their price objective on Cartesian Therapeutics from $42.00 to $44.00 and gave the stock a “buy” rating in a research note on Friday, November 14th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.50.

About Cartesian Therapeutics

Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian’s technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions.

At the core of Cartesian’s approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations.